| abstract |
The heteroaromatic compound having structural formula (I) is a selective inhibitor of stearoyl-coenzyme A delta-9 desaturase (SCD1) compared to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are associated with abnormal lipid synthesis and metabolism related conditions including cardiovascular disease, atherosclerosis, lipid disorders, obesity, diabetes, neurological disease, metabolic syndrome, insulin resistance and fatty liver disease. Useful for prevention and treatment. |